Supplementary Balance Sheet Information

9 Months Ended

Sep. 30, 2021

Balance Sheet Related Disclosures [Abstract]

Note 5 – Supplementary Balance Sheet Information

Property and equipment consist of the following (in thousands):

	September 30, 2021			December 31, 2020
Lab equipment	$	7,475		$	5,730
Leasehold improvements		2,037			1,845
Computer equipment		871			871
Furniture and fixtures		424			424
Software		655			651
Vehicles		97			—
Construction in process		268			381
		11,827			9,902
Less: accumulated depreciation		(7,395	)		(6,724	)
Total property and equipment, net	$	4,432		$	3,178

Depreciation expense for the three and nine months ended September 30, 2021 was $0.3 million and $0.8 million, respectively, compared to $0.2 million and $0.6 million for the three and nine months ended September 30, 2020, respectively. Noncash purchases of property and equipment included in ‘Accounts payable’ as of September 30, 2021 totaled $0.4 million.

Intangible assets, excluding goodwill, consist of the following (in thousands):

	September 30, 2021							December 31, 2020
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,667	$	(550	)	$	1,117	$	1,474	$	(494	)	$	980
Purchased technology		16,900		(6,102	)		10,798		16,900		(4,694	)		12,206
Intangible assets not subject to amortization
Trademarks		77		—			77		74		—			74
Total	$	18,644	$	(6,652	)	$	11,992	$	18,448	$	(5,188	)	$	13,260

Amortization expense related to definite-lived intangible assets was $0.5 million and $1.5 million for the three and nine months ended September 30, 2021 and $0.5 million and $1.6 million for the three and nine months ended September 30, 2020, respectively.

Future estimated amortization expense of intangible assets is (in thousands):

	As of
	September 30, 2021
Remainder of 2021	$	490
2022		1,959
2023		1,955
2024		1,948
2025		1,944
2026 and thereafter		3,619
Total	$	11,915

Accrued liabilities consist of the following (in thousands):

	September 30, 2021		December 31, 2020
Compensation related accruals	$	2,624	$	3,975
Accrued clinical trial expense		909		715
Other expenses		2,746		3,099
Total accrued liabilities	$	6,279	$	7,789